---
document_datetime: 2026-02-09 16:49:28
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exjade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: exjade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1603182
conversion_datetime: 2026-02-13 18:24:36.108011
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EXJADE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | A. ADMINISTRATIVE CHANGES - A.7 | 04/02/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323869                        | Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                                                                                                                                                                                            |            | PL                    |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|
| Variation type II / EMA/VR/0000280855    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section D of Annex II of the PI based on the submission of the final report from study CICL670E2422, listed as an imposed PASS in the Annex II. This is an observational study that evaluated the safety of deferasirox in the treatment of paediatric patients with non-transfusion- dependent iron overload. The RMP version 23.1 was agreed. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. | 27/11/2025 | SmPC, Annex II and PL |
| Variation type IA_IN / EMA/VR/0000292587 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/08/2025 | Annex II and PL       |

<div style=\"page-break-after: always\"></div>

| responsible include batch release - Accepted   |
|------------------------------------------------|